Ireland - English - HPRA (Health Products Regulatory Authority)

orion corporation - methotrexate - tablet - 10 milligram(s) - other immunosuppressants; methotrexate

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk) ltd - methotrexate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk) ltd - methotrexate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - methotrexate - oral tablet - 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

camurus pty ltd - buprenorphine, quantity: 160 mg - injection, solution - excipient ingredients: n-methyl-2-pyrrolidone; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on buvidal weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fentanyl citrate, quantity: 785 microgram (equivalent: fentanyl, qty 500 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - short duration analgesia during premedication, induction and maintenance of anaesthesia, and in the immediate postoperative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic premedication for the induction of anaesthesia, and as an adjunct in the maintanance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fentanyl citrate, quantity: 157 microgram (equivalent: fentanyl, qty 100 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - short duration analgesia during premedication, induction and maintenance of anaesthesia, and in the immediate postoperative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic premedication for the induction of anaesthesia, and as an adjunct in the maintanance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: disodium edetate; sodium hydroxide; water for injections - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects section of the cyclophosphamide and ifosfamide product information).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: disodium edetate; sodium hydroxide; water for injections - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects section of the cyclophosphamide and ifosfamide product information).

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.